# Effects of Rosiglitazone on fluid retention and insulin resistance in response to Head-out immersion in individuals with type 2 diabetes and impaired glucose tolerance.

Submission date	Recruitment status	<ul><li>Prospectively registered</li></ul>		
30/09/2004	No longer recruiting	☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
30/09/2004	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
15/05/2012	Nutritional, Metabolic, Endocrine			

## Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr Paul O'Hare

#### Contact details

Diabetes Centre St Cross Hospital Barby Road Rugby United Kingdom CV22 5PX

# Additional identifiers

**EudraCT/CTIS** number

**IRAS** number

ClinicalTrials.gov number

Secondary identifying numbers

# Study information

#### Scientific Title

#### Study objectives

Type 2 diabetes is linked to molecular mechanisms of insulin resistance. Rosiglitazone restores impaired sodium excretion in type 2 diabetes by causing increased insulin sensitivity in the kidneys and within the peripheral vasculature.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Not provided at time of registration

#### Study design

Randomised controlled trial

#### Primary study design

Interventional

#### Secondary study design

Randomised controlled trial

#### Study setting(s)

Not specified

# Study type(s)

**Not Specified** 

## Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

Nutritional, Metabolic, Endocrine: Diabetes

#### **Interventions**

Prospective Randomised Controlled Trial.

#### Intervention Type

Other

#### Phase

**Not Specified** 

#### Primary outcome measure

Insulin sensitivity before and after treatment and sodium excretion.

#### Secondary outcome measures

Not provided at time of registration

## Overall study start date

17/07/2002

## Completion date

10/12/2004

# **Eligibility**

#### Key inclusion criteria

Patients with Type 2 Diabetes and impaired glucose tolerance (48).

#### Participant type(s)

**Patient** 

#### Age group

**Not Specified** 

#### Sex

**Not Specified** 

#### Target number of participants

Not provided at time of registration

#### Key exclusion criteria

Does not meet inclusion criteria

#### Date of first enrolment

17/07/2002

#### Date of final enrolment

10/12/2004

# Locations

#### Countries of recruitment

England

**United Kingdom** 

#### Study participating centre

#### **Diabetes Centre**

Rugby United Kingdom CV22 5PX

# Sponsor information

#### Organisation

Department of Health

#### Sponsor details

Richmond House 79 Whitehall London United Kingdom SW1A 2NL

#### Sponsor type

Government

#### Website

http://www.dh.gov.uk/Home/fs/en

# Funder(s)

## Funder type

Hospital/treatment centre

#### **Funder Name**

University Hospitals Coventry and Warwickshire NHS Trust (UK)

# **Results and Publications**

## Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

# Not provided at time of registration

# Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/04/2008		Yes	No